BACKGROUND: Our group previously published data showing that @entity1 could be stratified by constructed molecular subtype with respect to locoregional recurrence (LRR)-free survival after neoadjuvant chemotherapy and breast-conserving therapy (BCT). That study predated use of trastuzumab for @entity1 @entity1722 ( @entity1722 )-positive @entity1 . The current study was undertaken to determine the impact of subtype and response to therapy in a contemporary cohort. METHODS: Clinicopathologic data from 751 @entity0 @entity1 who received neoadjuvant chemotherapy (with trastuzumab if @entity1722 (+)) and BCT from 2005 to 2012 were identified. @entity5282 ( @entity5282 ) and @entity1722 status were used to construct molecular subtypes: @entity5282 (+)/ @entity1722 (-) (n  =  369), @entity5282 (+)/ @entity1722 (+) (n  =  105), @entity5282 (-)/ @entity1722 (+) (n  =  58), and @entity5282 (-)/ @entity1722 (-) (n  =  219). Actuarial rates of LRR were determined by the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was performed to determine factors associated with LRR. RESULTS: The pathologic complete response (pCR) rates by subtype were as follows: 16.5  % ( @entity5282 (+)/ @entity1722 (-)), 45.7  % ( @entity5282 (+)/ @entity1722 (+)), 72.4  % ( @entity5282 (-)/ @entity1722 (+)), and 42.0  % ( @entity5282 (-)/ @entity1722 (-)) (P  <  0.001). Median follow-up was 4.6  years. The 5-year LRR-free survival rate for all @entity1 was 95.4  %. Five-year LRR-free survival rates by subtype were 97.2  % ( @entity5282 (+)/ @entity1722 (-)), 96.1  % ( @entity5282 (+)/ @entity1722 (+)), 94.4  % ( @entity5282 (-)/ @entity1722 (+)), and 93.4  % ( @entity5282 (-)/ @entity1722 (-)) (P  =  0.44). For @entity1 with @entity5282 (-)/ @entity1722 (+) disease, the LRR-free survival rates were 97.4 and 86.7  % for those who did and those who did not experience pCR, respectively. For @entity1 with @entity5282 (-)/ @entity1722 (-) disease, the LRR-free survival rates were 98.6  % (pCR) versus 89.9  % (no pCR). On multivariate analysis, the @entity5282 (-)/ @entity1722 (-) subtype, clinical stage III disease, and failure to experience a pCR were associated with LRR. CONCLUSIONS: @entity1 undergoing BCT after neoadjuvant chemotherapy have excellent rates of 5-year LRR-free survival that are affected by molecular subtype and by response to neoadjuvant chemotherapy.

Locoregional Control According to @entity0 Subtype and Response to Neoadjuvant Chemotherapy in @entity0 XXXX Undergoing Breast-conserving Therapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity5282 :: ('3164', 'Gene') :: ['HR', 'Hormone receptor'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1722 :: ('2064', 'Gene') :: ['epidermal growth factor receptor 2', 'HER2']
@entity1 :: (9606,Species) :: ['Patients']
